Associated Genetic Biomarkers
SMC1A Loss serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains SMC1A Loss as an inclusion criterion, 1 is phase 1 (1 open).
Trials with SMC1A Loss in the inclusion eligibility criteria most commonly target acute myeloid leukemia and myelodysplastic syndromes .
Talazoparib is the most frequent therapy in trials with SMC1A Loss as an inclusion criteria .
Significance of SMC1A Loss in Diseases
Acute Myeloid Leukemia +
SMC1A is altered in 0.68% of acute myeloid leukemia patients .
SMC1A Loss is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMC1A Loss and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) .
Myelodysplastic Syndromes +
SMC1A is altered in 0.35% of myelodysplastic syndromes patients .
SMC1A Loss is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains SMC1A Loss and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.